Fiche du document
2011
- doi: 10.1093/rheumatology/keq350
- issn: 1462-0324
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/rheumatology/keq350
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/21097449
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1462-0332
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3CAB57DB17476
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Citer ce document
M. Ostensen et al., « Pregnancy and reproduction in autoimmune rheumatic diseases. », Serveur académique Lausannois, ID : 10.1093/rheumatology/keq350
Métriques
Partage / Export
Résumé
Despite evidence for the important role of oestrogens in the aetiology and pathophysiology of chronic immune/inflammatory diseases, the previous view of an unequivocal beneficial effect of oestrogens on RA compared with a detrimental effect on SLE has to be reconsidered. Likewise, the long-held belief that RA remits in the majority of pregnant patients has been challenged, and shows that only half of the patients experience significant improvement when objective disease activity measurements are applied. Pregnancies in patients with SLE are mostly successful when well planned and monitored interdisciplinarily, whereas a small proportion of women with APS still have adverse pregnancy outcomes in spite of the standard treatment. New prospective studies indicate better outcomes for pregnancies in women with rare diseases such as SSc and vasculitis. Fertility problems are not uncommon in patients with rheumatic disease and need to be considered in both genders. Necessary therapy, shortly before or during the pregnancy, demands taking into account the health of both mother and fetus. Long-term effects of drugs on offspring exposed in utero or during lactation is a new area under study as well as late effects of maternal rheumatic disease on children.